IP Library › Granted Patent US 12,247,073
Granted Patent B2
US 12,247,073 · App. 17/272,083 · Granted Mar 11, 2025

Anti-CD33 antibodies and methods of use thereof

Inventors: Patricia Culp (Oakland, CA); Helen Lam (Union City, CA); Wei-Hsien Ho (Belmont, CA); Leonard G. Presta (Palo Alto, CA); Arnon Rosenthal (Woodside, CA)
Assignee: ALECTOR LLC
C07K16/2803C07K2317/24C07K2317/31C07K2317/52C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,073
App. No.
17/272,083
Granted
Mar 11, 2025
Kind
B2
Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Claims (120)

1. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region comprising an HVR-H1, HVR-H2, and HVR-H3 and a light chain variable region comprising an HVR-L1, HVR-L2, and HVR-L3, wherein

the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60;

the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62;

the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61; or

the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61.

2. The antibody of claim 1 , wherein the antibody comprises

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 101;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102; or

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.

3. A monoclonal antibody that binds to human CD33, wherein the antibody comprises

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 101;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102; or

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.

4. The antibody of claim 1 , wherein the antibody is of the IgG class, the IgM class, or the IgA class.

5. The antibody of claim 4 , wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype.

6. The antibody of claim 5 , wherein the antibody comprises one or more amino acid substitutions in the Fc region at a residue position selected from the group consisting of: C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, wherein the numbering of the residues is according to EU numbering.

7. The antibody of claim 5 , wherein the antibody has an IgG4 isotype, and wherein the antibody comprises an S228P amino acid substitution at residue position 228, an F234A amino acid substitution at residue position 234, and an L235A amino acid substitution at residue position 235, wherein the numbering of the residue position is according to EU numbering.

8. The antibody of claim 6 , wherein:

(a) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of the residue position is according to EU numbering;

(b) the Fc region comprises an amino acid substitution at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering;

(c) the Fc region comprises an amino acid substitution at positions L234A, L235A, P331S, and E430G, wherein the numbering of the residue position is according to EU numbering;

(d) the Fc region comprises an amino acid substitution at positions K322A and E430G, wherein the numbering of the residue position is according to EU numbering;

(e) the Fc region comprises an amino acid substitution at positions P331S and E430G, wherein the numbering of the residue position is according to EU numbering;

(f) the Fc region comprises an amino acid substitution at positions A330S, P331S, and E430G, wherein the numbering of the residue position is according to EU numbering;

(g) the Fc region comprises an amino acid substitution at positions K322A, A330S, and P331S, wherein the numbering of the residue position is according to EU numbering;

(h) the Fc region comprises an amino acid substitution at positions K322A, P331S, and E430G, wherein the numbering of the residue position is according to EU numbering;

(i) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of the residue position is according to EU numbering;

(j) the Fc region comprises an amino acid substitution at positions A330S, P331S, and E430G, wherein the numbering of the residue position is according to EU numbering;

(k) the Fc region comprises an amino acid substitution at positions S267E and L328F, wherein the numbering of the residue position is according to EU numbering;

(l) the Fc region comprises an amino acid substitution at position C127S, wherein the numbering of the residue position is according to EU numbering;

(m) the Fc region comprises an amino acid substitution at positions E345R, E430G and S440Y, wherein the numbering of the residue position is according to EU numbering;

(n) the Fc region comprises an amino acid substitution at position P331S, wherein the numbering of the residue position is according to EU numbering; or

(o) the Fc region comprises an amino acid substitution at positions L234A, L235A, P331S, wherein the numbering of the residue positions is according to EU numbering.

9. The antibody of claim 1 , wherein the CD33 protein is a mammalian protein or a human protein.

10. The antibody of claim 1 , wherein the CD33 protein is a wild-type protein.

11. The antibody of claim 1 , wherein the CD33 protein is a naturally occurring variant.

12. The antibody of claim 1 , wherein the CD33 protein is expressed on one or more cells selected from the group consisting of human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human T helper cell, human cytotoxic T cells, human granulocytes, and human microglia.

13. The antibody of claim 1 , wherein the antibody binds specifically to a human CD33 protein.

14. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on human CD33 or a mammalian CD33 protein.

15. The antibody of claim 14 , wherein the fragment is an Fab, Fab′, Fab′-SH, F(ab′) 2 , Fv, or scFv fragment.

16. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, a naturally occurring variant of human CD33, and a disease variant of human CD33.

17. The antibody of claim 14 , wherein the antibody fragment is cross-linked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, a naturally occurring variant of human CD33, and a disease variant of human CD33.

18. The antibody of claim 1 , wherein the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.

19. The antibody of claim 18 , wherein the antibody is a monoclonal antibody.

20. The antibody of claim 18 , wherein the antibody is a bispecific antibody recognizing a first antigen and a second antigen.

21. The antibody of claim 20 , wherein the first antigen is CD33 and the second antigen is:

(a) an antigen facilitating transport across the blood-brain-barrier;

(b) an antigen facilitating transport across the blood-brain-barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, a llama single domain antibody, TMEM 30 (A), a protein transduction domain, TAT, Syn-B, penetratin, a poly-arginine peptide, an angiopep peptide, and ANG1005;

(c) a disease-causing agent selected from the group consisting of disease-causing peptides or proteins and disease-causing nucleic acids, wherein the disease-causing peptides or proteins are selected from the group consisting of amyloid beta, oligomeric amyloid beta, amyloid beta plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9or f72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta 2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, Repeat-associated non-ATG (RAN) translation products, DiPeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides, and the disease-causing nucleic acids are antisense GGCCCC (G2C4) repeat-expansion RNA;

(d) ligands and/or proteins expressed on immune cells, wherein the ligands and/or proteins are selected from the group consisting of CD40, OX40, ICOS, CD28, CD137/4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine;

(e) a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells;

or

(f) a Lewy body.

22. The antibody of claim 1 , wherein the antibody has a dissociation constant (KD) for human CD33 that is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D is determined by BioLayer Interferometry.

23. The antibody of claim 1 , wherein the antibody has a dissociation constant (K D ) for human CD33 that ranges from about 2 nM to about 200 pM, or less than about 200 pM, and wherein the K D is determined by BioLayer Interferometry.

24. The antibody of claim 1 , wherein the antibody reduces cell surface levels of CD33.

25. The antibody of claim 24 , wherein the CD33 is expressed on the surface of human dendritic cells.

26. The antibody of claim 24 , wherein the antibody reduces cell surface levels of CD33 in vitro.

27. The antibody of claim 24 , wherein the antibody reduces cell surface levels of CD33 in vitro with a half maximal effective concentration (EC 50 ) that is less than 40 pM, as measured by flow cytometry.

28. The antibody of claim 1 , wherein the antibody increases expression of one or more disease-associated microglia (DAM) markers.

29. The antibody of claim 28 , wherein the one or more DAM markers is ApoE3, Tyrobp, B2m, Trem2, Cst7, Cts1, Lp1, Cd9, Ax1, Csf1, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.

30. The antibody of claim 1 , wherein the antibody comprises an Fc region comprising the amino acid sequence of SEQ ID NO: 118.

31. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 1 .

32. A vector comprising the nucleic acid of claim 31 .

33. An isolated host cell comprising the vector of claim 32 .

34. A method of producing an antibody that binds to CD33, comprising culturing the cell of claim 33 so that the antibody is produced.

35. The method of claim 34 , further comprising recovering the antibody produced by the cell.

36. An isolated antibody that binds to CD33 produced by the method of claim 34 .

37. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

38. A method of treating a disease selected from the group consisting of Alzheimer's disease, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma, comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 1 .

39. The method of claim 38 , wherein the disease is Alzheimer's disease.

40. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and wherein the light chain variable region comprises: an HVR-L1 comprising the amino acid sequence of SEQ ID NO:47, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61.

41. The antibody of claim 40 , wherein the antibody binds specifically to a human CD33 protein.

42. The antibody of claim 40 , wherein the antibody has a dissociation constant (K D ) for human CD33 that is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D is determined by BioLayer Interferometry.

43. The antibody of claim 40 , wherein the antibody has a dissociation constant (KD) for human CD33 that ranges from about 2 nM to about 200 pM, or less than about 200 pM, and wherein the Kp is determined by BioLayer Interferometry.

44. The antibody of claim 40 , wherein the antibody reduces cell surface levels of CD33.

45. The antibody of claim 44 , wherein the CD33 is expressed on the surface of human dendritic cells.

46. The antibody of claim 44 , wherein the antibody reduces cell surface levels of CD33 in vitro.

47. The antibody of claim 44 , wherein the antibody reduces cell surface levels of CD33 in vitro with a half maximal effective concentration (EC 50 ) that is less than 40 pM, as measured by flow cytometry.

48. The antibody of claim 40 , wherein the antibody increases expression of one or more disease-associated microglia (DAM) markers.

49. The antibody of claim 48 , wherein the one or more DAM markers is ApoE3, Tyrobp, B2m, Trem2, Cst7, Cts1, Lp1, Cd9, Ax1, Csf1, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.

50. The antibody of claim 40 , wherein the antibody is a monoclonal antibody.

51. The antibody of claim 40 , wherein the antibody has an IgG2 isotype.

52. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 40 .

53. A vector comprising the nucleic acid of claim 52 .

54. An isolated host cell comprising the vector of claim 53 .

55. A method of producing an antibody that binds to CD33, comprising culturing the cell of claim 54 so that the antibody is produced.

56. The method of claim 55 , further comprising recovering the antibody produced by the cell.

57. An isolated antibody that binds to CD33 produced by the method of claim 56 .

58. A pharmaceutical composition comprising the antibody of claim 40 and a pharmaceutically acceptable carrier.

59. A method of treating Alzheimer's disease, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma, comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 40 .

60. The method of claim 59 , wherein the disease is Alzheimer's disease.

61. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.

62. The antibody of claim 61 , wherein the antibody is a monoclonal antibody.

63. The antibody of claim 61 , wherein the antibody has an IgG2 isotype.

64. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 61 .

65. A vector comprising the nucleic acid of claim 64 .

66. An isolated host cell comprising the vector of claim 65 .

67. A method of producing an antibody that binds to CD33, comprising culturing the cell of claim 66 so that the antibody is produced.

68. The method of claim 67 , further comprising recovering the antibody produced by the cell.

69. An isolated antibody that binds to CD33 produced by the method of claim 68 .

70. A pharmaceutical composition comprising the antibody of claim 61 and a pharmaceutically acceptable carrier.

71. A method of treating Alzheimer's disease, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma, comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 43 .

72. The method of claim 71 , wherein the disease is Alzheimer's disease.

73. An isolated antibody that binds to CD33, wherein the antibody comprises

(a) a heavy chain comprising the amino acid sequence of SEQ ID. NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or

(b) a heavy chain comprising the amino acid sequence of SEQ ID. NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122.

74. The antibody of claim 73 , wherein the antibody is a monoclonal antibody.

75. The antibody of claim 73 , wherein the antibody has an IgG2 isotype.

76. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 73 .

77. A vector comprising the nucleic acid of claim 76 .

78. An isolated host cell comprising the vector of claim 77 .

79. A method of producing an antibody that binds to CD33, comprising culturing the cell of claim 78 so that the antibody is produced.

80. The method of claim 79 , further comprising recovering the antibody produced by the cell.

81. An isolated antibody that binds to CD33 produced by the method of claim 80 .

82. A pharmaceutical composition comprising the antibody of claim 73 and a pharmaceutically acceptable carrier.

83. A method of treating Alzheimer's disease, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma, comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 44 .

84. The method of claim 83 , wherein the disease is Alzheimer's disease.

Assignments (2)
SECURITY INTEREST Recorded Nov 14, 2024
From: ALECTOR, INC.; ALECTOR LLC
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 069386/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2022
From: CULP, PATRICIA; LAM, HELEN; HO, WEI-HSIEN; PRESTA, LEONARD; ROSENTHAL, ARNON
To: ALECTOR LLC
Reel/Frame 060868/0426 →
Continuity (2)
Provisional Application 62726053 · Aug 31, 2018
Related Publication 20210317208A1 · Oct 14, 2021
References Cited (400)
US 4469863A · Ts'o et al. · 1984 [cited by applicant]
US 4657760A · Kung et al. · 1987 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5225212A · Martin et al. · 1993 [cited by applicant]
US 5229275A · Goroff et al. · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5536821A · Agrawal et al. · 1996 [cited by applicant]
US 5541306A · Agrawal et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5567610A · Borrebaeck et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5573905A · Lerner et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5614622A · Iyer et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5637683A · Usher et al. · 1997 [cited by applicant]
US 5637684A · Cook et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648237A · Carter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5700922A · Cook · 1997 [cited by applicant]
US 5717083A · Cook et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5730982A · Scheinberg · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5739308A · Kandimalla et al. · 1998 [cited by applicant]
US 5739314A · Roy et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5773601A · Agrawal · 1998 [cited by applicant]
US 5789199A · Joly et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5840523A · Simmons et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5869619A · Studnicka · 1999 [cited by applicant]
US 5886165A · Kandimalla et al. · 1999 [cited by applicant]
US 5929226A · Padmapriya et al. · 1999 [cited by applicant]
US 5955599A · Iyer et al. · 1999 [cited by applicant]
US 5959177A · Hein et al. · 1999 [cited by applicant]
US 5962674A · Iyer et al. · 1999 [cited by applicant]
US 5977296A · Nielsen et al. · 1999 [cited by applicant]
US 6040498A · Stomp et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6117992A · Iyer · 2000 [cited by applicant]
US 6140482A · Iyer et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 6417429B1 · Hein et al. · 2002 [cited by applicant]
US 6420548B1 · Vézina et al. · 2002 [cited by applicant]
US 6455308B1 · Freier · 2002 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7041870B2 · Tomizuka et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7125978B1 · Vézina et al. · 2006 [cited by applicant]
US 7189826B2 · Rodman · 2007 [cited by applicant]
US 7342110B2 · Hoffee et al. · 2008 [cited by applicant]
US 7420041B2 · Young et al. · 2008 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 7557189B2 · Hoffee et al. · 2009 [cited by applicant]
US 7566772B2 · Green et al. · 2009 [cited by applicant]
US 8119787B2 · Hoffee et al. · 2012 [cited by applicant]
US 8124069B2 · Bae et al. · 2012 [cited by applicant]
US 8337855B2 · Hoffee et al. · 2012 [cited by applicant]
US 8614299B2 · Baurin et al. · 2013 [cited by applicant]
US 9765157B2 · Xiao et al. · 2017 [cited by applicant]
US 9951133B2 · Yu et al. · 2018 [cited by applicant]
US 10711062B2 · Culp et al. · 2020 [cited by applicant]
US 11136390B2 · Monroe et al. · 2021 [cited by applicant]
US 11174313B2 · Rosenthal et al. · 2021 [cited by applicant]
US 11254743B2 · Culp et al. · 2022 [cited by applicant]
US 20070061900A1 · Murphy et al. · 2007 [cited by applicant]
US 20070148167A1 · Strohl · 2007 [cited by applicant]
US 20070292936A1 · Barthelemy et al. · 2007 [cited by applicant]
US 20090002360A1 · Chen et al. · 2009 [cited by applicant]
US 20090181855A1 · Vasquez et al. · 2009 [cited by applicant]
US 20100056386A1 · Vasquez et al. · 2010 [cited by applicant]
US 20100280227A1 · Ambrose et al. · 2010 [cited by applicant]
US 20120082670A1 · Konopitzky et al. · 2012 [cited by applicant]
US 20130309223A1 · Sutherland et al. · 2013 [cited by applicant]
US 20160038566A1 · Tanzi et al. · 2016 [cited by applicant]
US 20190002560A1 · Monroe et al. · 2019 [cited by applicant]
US 20190040131A1 · Culp et al. · 2019 [cited by applicant]
US 20190085076A1 · Rosenthal et al. · 2019 [cited by applicant]
US 20210139581A1 · Culp et al. · 2021 [cited by applicant]
US 20220162309A1 · Culp et al. · 2022 [cited by applicant]
US 20220251190A1 · Monroe et al. · 2022 [cited by applicant]
US 20220281976A1 · Rosenthal et al. · 2022 [cited by applicant]
US 20230035072A1 · Robert et al. · 2023 [cited by applicant]
CA 2988982A1 · 2016 [cited by applicant]
CN 1078401A · 1993 [cited by applicant]
CN 1795009A · 2006 [cited by applicant]
CN 102952191A · 2013 [cited by applicant]
CN 103261227A · 2013 [cited by applicant]
CN 104936617A · 2015 [cited by applicant]
CN 107922480A · 2018 [cited by applicant]
CN 112912144A · 2021 [cited by applicant]
EP 308936B1 · 1994 [cited by applicant]
EP 404097B1 · 1996 [cited by applicant]
EP 546073B1 · 1997 [cited by applicant]
IL 235733B · 2021 [cited by applicant]
JP 2006505277A · 2006 [cited by applicant]
JP 2014500003A · 2014 [cited by applicant]
JP 2015520758A · 2015 [cited by applicant]
JP 2018518176A · 2018 [cited by applicant]
JP 7299160B2 · 2023 [cited by applicant]
KR 20050059332A · 2005 [cited by applicant]
KR 20150013321A · 2015 [cited by applicant]
TW 201408700A · 2014 [cited by applicant]
WO WO1987004462A1 · 1987 [cited by applicant]
WO WO1991000360A1 · 1991 [cited by applicant]
WO WO1991009058A1 · 1991 [cited by applicant]
WO WO1991010741A1 · 1991 [cited by applicant]
WO WO1992000373A1 · 1992 [cited by applicant]
WO WO1992020373A1 · 1992 [cited by applicant]
WO WO1993001161A1 · 1993 [cited by applicant]
WO WO1993008829A1 · 1993 [cited by applicant]
WO WO1993011161A1 · 1993 [cited by applicant]
WO WO1993016185A2 · 1993 [cited by applicant]
WO WO1993020848A1 · 1993 [cited by applicant]
WO WO1994004690A1 · 1994 [cited by applicant]
WO WO1996027011A1 · 1996 [cited by applicant]
WO WO1996033735A1 · 1996 [cited by applicant]
WO WO1996034096A1 · 1996 [cited by applicant]
WO WO1997011971A1 · 1997 [cited by applicant]
WO WO1997017852A1 · 1997 [cited by applicant]
WO WO1998024893A2 · 1998 [cited by applicant]
WO WO1999032619A1 · 1999 [cited by applicant]
WO WO1999058572A1 · 1999 [cited by applicant]
WO WO2000044895A1 · 2000 [cited by applicant]
WO WO2000056746A2 · 2000 [cited by applicant]
WO WO2000075372A1 · 2000 [cited by applicant]
WO WO2001014398A1 · 2001 [cited by applicant]
WO WO2001029058A1 · 2001 [cited by applicant]
WO WO2001036646A1 · 2001 [cited by applicant]
WO WO2003024993A2 · 2003 [cited by applicant]
WO WO2003093298A2 · 2003 [cited by applicant]
WO WO2004042072A2 · 2004 [cited by applicant]
WO WO2004043344A2 · 2004 [cited by applicant]
WO WO2007014743A2 · 2007 [cited by applicant]
WO WO2007106585A1 · 2007 [cited by applicant]
WO WO2008058021A2 · 2008 [cited by applicant]
WO WO2008079246A2 · 2008 [cited by applicant]
WO WO2009036379A2 · 2009 [cited by applicant]
WO WO2010105256A1 · 2010 [cited by applicant]
WO WO2011036183A2 · 2011 [cited by applicant]
WO WO2011038301A2 · 2011 [cited by applicant]
WO WO2012009568A2 · 2012 [cited by applicant]
WO WO2012045752A1 · 2012 [cited by applicant]
WO WO2012074097A1 · 2012 [cited by applicant]
WO WO2013173496A2 · 2013 [cited by applicant]
WO WO2016052756A1 · 2016 [cited by examiner]
WO WO2016087651A1 · 2016 [cited by applicant]
WO WO2016201388A2 · 2016 [cited by examiner]
WO WO2016201389A2 · 2016 [cited by applicant]
WO WO2019224711A2 · 2019 [cited by applicant]
WO WO2020047452A2 · 2020 [cited by applicant]
WO WO2021119400A1 · 2021 [cited by applicant]
Nelson. Antibody Fragments. mAbs 2010; 2(1):77-83. (Year: 2010). [cited by examiner]
Prins and Scheltens. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research & Therapy. 2013; (5)56:1-6. (Year: 2013). [cited by examiner]
Frenzel et al. Expression of recombinant antibodies. Front Immunol, 2013 4:1-20 (Year: 2013). [cited by examiner]
Sumner et al. Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease Disease Front Neurosci, 2018 12(254): 1-12. (Year: 2018). [cited by examiner]
Bhattacherjee et al., (2019). “Repression of phagocytosis by human CD33 is not conserved with mouse CD33,” Commun Biol., 2:450, 13 pages. [cited by applicant]
Bostrom et al., (2009). “Improving antibody binding affinity and specificity for therapeutic development,” Methods Mol Biol., 525:353-76. [cited by applicant]
Candia et al., (2017). “Assessment of Variability in the SOMAscan Assay,” Sci Rep, 7:14248, 13 pages. [cited by applicant]
Caron et al., (1992). “Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies,” Cancer Research, 52(24):6761-7. [cited by applicant]
Declaration of Dr. Rudolph Emile Tanzi submitted before the European Patent Office for EP patent application No. 14773553.4, filed Mar. 27, 2014, dated Jun. 14, 2021, 8 pages. [cited by applicant]
Gonzales et al., (2005). “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumour Biol., 26(1):31-43. [cited by applicant]
Jiang et al., (2018). “Meta-analysis of the association between CD33 and Alzheimer's disease” Ann Transl Med., 6(10):169, 12 pages. [cited by applicant]
Kunik et al., (2012). “Structural consensus among antibodies defines the antigen binding site,” PLoS Comput Biol., 8(2):e1002388, 12 pages. [cited by applicant]
Leoh et al., (2015). “Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1,” Molecular Immunology, 67:407-415, 22 pages. [cited by applicant]
Malik et al., (2015). “Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia,” Human Molecular Genetics, 24(12):3557-3570. [cited by applicant]
Mimoto et al., (2013). “Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa [cited by applicant]
O'Bryant et al., (2010). “Validation of the New Interpretive Guidelines for the Clinical Dementia Rating Scale Sum of Boxes Score in the National Alzheimer's Coordinating Center Database,” Arch Neurol, 67(6):746-49, 9 p… [cited by applicant]
Ovacik et al., (2018). “Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development,” Clin Transl Sci, 11(6):540-552. [cited by applicant]
Parekh et al., (2012). “Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay,” MAbs, 4(3):310-318. [cited by applicant]
Schwartz et al., (2003). “Formalization of the MESF unit of fluorescence intensity,” Cytometry Part B (Clinical Cytometry), 57B:1-6. [cited by applicant]
Sela-Culang et al., (2013). “The Structural Basis of Antibody-Antigen Recognition,” Front Immunol, 4:302, 13 pages. [cited by applicant]
Wark et al., (2006). “Latest technologies for the enhancement of antibody affinity,” Advanced Drug Delivery Reviews, 58(5-6):657-670. [cited by applicant]
Wu et al., (1999). “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol., 294:151-162. [cited by applicant]
Yu et al., (2013). “Developing therapeutic antibodies for neurodegenerative disease,” Neurotherapeutics, 10:459-472. [cited by applicant]
Zhang et al., (2014). “Progress in Antibody-Drug Conjugates Directed against CD33,” Chinese Journal of Cell Biology, 36(1):106-114. English abstract only. [cited by applicant]
Zhao, (2019). “CD33 in Alzheimer's Disease—Biology, Pathogenesis, and Therapeutics: A Mini-Review,” Gerontology, 65:323-331. [cited by applicant]
Chinese Search Report search date Feb. 24, 2023 for Chinese Application No. 201880027790.9, 5 pages. English translation. [cited by applicant]
Singaporean Search Report received for Singaporean Application No. 11202101552S date of completion Aug. 11, 2022, 2 pages. [cited by applicant]
Written Decision revoking European Patent EP2978446 mailed on Jun. 13, 2022, 14 pages. [cited by applicant]
Liang et al., (2008). “Application of the CD33 Monoclonal Antibody GO in the Treatment of Leukemia,” National Medical Frontiers of China, 3(19):34-36. English abstract only. [cited by applicant]
Alegre et al., (1994). “A Non-Activating “Humanized” Anti-cd3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo,” Transplantation, 57(11):1537-1543. [cited by applicant]
Almagro et al., (2008). “Humanization of Antibodies,” Frontiers in Bio-Science, 13:1619-1633. [cited by applicant]
Al-Shawi et al., (2008). “Neurotoxic and Neurotrophic Roles of proNGF and the Receptor Sortilin in the Adult and Ageing Nervous System,” European Journal of Neuroscience, 27:2103-2114. [cited by applicant]
Angal et al., (1993). “A Single Amino Acid Substitution Abolishes The Heterogeneity Of Chimeric Mouse/Human (IgG4) Antibody,” Molecular Immunology, 30(1):105-108. [cited by applicant]
Anonymous, (2019). “EC50,” Available online at: <en.wikipedia.org/wiki/EC50>, Sep. 16, 2019, 3 pages. [cited by applicant]
Applicant response to summons for European Patent Application No. 14773553.4 filed on Oct. 12, 2019, 10 pages. [cited by applicant]
Armour et al., (1999). “Recombinant Human IgG Molecules Lacking FcGamma Receptor I Binding and Monocyte Triggering Activities,” Eur. J. Immunol. 29:2613-2624. [cited by applicant]
Armour et al., (2000). “Mutant IgG Lacking FcγRIII Binding and ADCC Activities,”The Haematology Journal, poster Session 1, Presented at the 5th Annual Meeting of the European Haematology Association, Birmingham, UK, 1(S… [cited by applicant]
Armour et al., (2003). “Differential Binding To Human Fcγriia and Fcγriib Receptors by Human IgG Wildtype and Mutant Antibodies,” Molecular Immunology, 40:585-593. [cited by applicant]
Arnett et al., (Dec. 5, 2007; e-published on Oct. 26, 2007). “proNGF, Sortilin, and p75NTR: Potential Mediators of Injury-Induced Apoptosis in the Mouse Dorsal Root Ganglion,” Brain Res., 1183:32-42. [cited by applicant]
Asquith et al., (2009). “Animal Models of Rheumatoid Arthritis,” Eur. J. Immunol., 39:2040-2044. [cited by applicant]
Attrill et al., (Oct. 27, 2006; e-published on Aug. 8, 2006). “Siglec-7 Undergoes a Major Conformational Change When Complexed with the α(2,8)-Disialylganglioside GT1b,” J. Biol. Chem., 281:32774-32783. [cited by applicant]
Baca et al., (1997). “Antibody Humanization Using Monovalent Phage Display,” The Journal of Biological Chemistry, 272(16):10678-10684. [cited by applicant]
Balaian et al., (2001). “Direct Effect of Bispecific Anti-CD33 X Anti-CD64 Antibody on Proliferation and Signaling in Myeloid Cells,” Leuk Res., 25(12):1115-1125. [cited by applicant]
Barbas III et al., (1994). “In Vitro Evolution of A Neutralizing Human Antibody To Human Immunodeficiency Virus Type 1 To Enhance Affinity And Broaden Strain Cross-Reactivity,” Proc Nat. Acad. Sci. USA, 91:3809-3813. [cited by applicant]
Bartholomaeus et al., (2014). “Cell Contact-Dependent Priming and Fe Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response,” The Journal of Immunology, 192:2091-2098. [cited by applicant]
Beattie et al., (2002). “ProNGF Induces p75-Mediated Death of Oligodendrocytes following Spinal Cord Injury,” Neuron, 36(3):375-386. [cited by applicant]
Bertram et al., (2008). “Genome-wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE,” Am. J. Hum. Genet., 83(5):623-632. [cited by applicant]
Boerner et al., (1991). “Production Of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes,” Journal of Immunology, 147(1):86-95. [cited by applicant]
Bolt et al., (1993). “The Generation Of A Humanized, Non-Mitogenic Cd3 Monoclonal Antibody Which Retains In Vitro Immunosuppressive Properties,” European Journal Immunol., 23:403-411. [cited by applicant]
Bradshaw et al., (Jul. 2013; e-published on May 23, 2013). “CD33 Alzheimer's Disease Locus: Altered Monocyte Function and Amyloid Biology,” Nat. Neurosci., 16(7):848-850, fourteen pages. [cited by applicant]
Brehm et al., (2010). “Humanized Mouse Models to Study Human Diseases,” Curr Opin Endocrinol Diabetes Obes., 17(2):120-125. [cited by applicant]
Brennan et al., (1985). “Preparation Of Bispecific Antibodies By Chemical Recombination Of Monoclonal Immunoglobulin G1 Fragments,” Science, 229:81-83. [cited by applicant]
Brinkman-Van Der Linden et al., (2003). “CD33/Siglec-3 Binding Specificity, Expression Pattern, and Consequences of Gene Deletion in Mice,” Mol. Cell Biol., 23(12):4199-4206. [cited by applicant]
Bross et al., (2001). “Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia,” Clinical Cancer Researc,h 7:1490-1496. [cited by applicant]
Bruggemann et al., (1993). “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals,” Year in Immunol., 7:33-40. [cited by applicant]
Callige et al., (2005). “CSN5/Jab1 is Involved in Ligand-Dependent Degradation of Estrogen Receptor α by the Proteasome,” Mol. Cell Biol., 25(11):4349-4358. [cited by applicant]
Cantoni et al., (2015). “Trem2 Regulates Microglial Cell Activation In Response To Demyelination In Vivo,” Acta Neuropathol,, 129(3):429-447, thirty three pages. [cited by applicant]
Cao et al., (2011). “Macrophage Polarization In The Maculae Of Age-Related Macular Degeneration: A Pilot Study,” Pathology International, 61(9):528-535, fourteen pages. [cited by applicant]
Capel et al., (1994). “Heterogeneity of Human IgG Fc Receptors,” Immunomethods, 4:25-34. [cited by applicant]
Carter et al., (1992). “High Level [cited by applicant]
Carter et al., (1992). “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci., USA 89:4285-4289. [cited by applicant]
Chan et al., (2010). “Therapeutic antibodies for autoimmunity and inflammation,” Nat. Rev. Immunol., 10:301-316. [cited by applicant]
Chang et al., (2002). “Retinal Degeneration Mutants In The Mouse,” Vision Research, 42:517-525. [cited by applicant]
Chen et al., (1999). “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Biol., 293:865-881. [cited by applicant]
Cheung, et al., (1990). “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks,” Virology, 176:546-552. [cited by applicant]
Chothia et al., (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol,, 196:901-917. [cited by applicant]
Chu et al., (2008; e-pub. Aug. 8, 2008). “Inhibition of B cell Receptor-Mediated Activation of Primary Human B Cells by Coengagement of CD19 and FcyRIIb with Fe-Engineered Antibodies,” Molecular Immunology, 45:3926-3933. [cited by applicant]
Clackson et al., (1991). “Making Antibody Fragments Using Phage Display Libraries,” Nature, 352(15):624-628. [cited by applicant]
Cole et al., (1999). “HuM291, A Humanized Anti-Cd3 Antibody is Immunosuppressive to T Cells While Exhibiting Reduced Mitogenicity in Vitro,” Transplantation, 68(4):563-571. [cited by applicant]
Compston et al., (2008). “Multiple Sclerosis,” Lancet 372(9648):1502-1517. [cited by applicant]
Correale et al., (2013). “Bacterial Sensor Triggering Receptor Expressed on Myeloid Cells-2 Regulates the Mucosal Inflammatory Response,” Gastroenterology, 144(2):346-356. [cited by applicant]
Crocker et al., (1999). “Molecular Analysis of Sialoside Binding to Sialoadhesin by NMR and Site-Directed Mutagenesis,” Biochem, J. 341 (Pt. 2):355-361. [cited by applicant]
Crocker et al., (2007). “Siglecs and their Roles in the Immune System,” Nat Rev Immunol., 7(4):255-266. [cited by applicant]
Crocker et al., (Apr. 2012; e-published on Feb. 21, 2012). “CD33-related Siglecs as Potential Modulators of Inflammatory Responses,” Ann. NY Acad. Sci., 1253:102-111. [cited by applicant]
Crocker et al., (Jun. 1, 2001). “Siglecs, Sialic Acids and Innate Immunity,” Trends Immunol., 22(6):337-342. [cited by applicant]
Cruts et al., (2008, e-pub. Mar. 6, 2008). “Loss of Progranulin Function in Frontotemporal Lobar Degeneration,” Trends Genetics, 24(4):186-194. [cited by applicant]
Cunningham et al., (1989). “High-Resolution Epitope Mapping Of hGH-Receptor Interactions By Alanine-Scanning Mutagenesis,” Science, 244:1081-1085. [cited by applicant]
Daeron, M., (1997). “FC Receptor Biology,” Annu. Rev. Immunol., 15:203-234. [cited by applicant]
Dall' Acqua et al., (2006). “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal Of Biological Chemistry, 281(33):23514-23524. [cited by applicant]
Daneman et al., (2010). “The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells,” PloS One, 5(10):e13741, 16 pages. [cited by applicant]
Davis et al., (2007). “Abatacept Binds To The Fc Receptor Cd64 But Does Not Mediate Complement-Dependent Cytotoxicity Or Antibody-Dependent Cellular Cytotoxicity,” The Journal of Rheumatology, 34(11):2204-2210. [cited by applicant]
De Haas et al., (1995). “Fcγ Receptors of Phagocytes,” J. Lab. Clin. Med., 126(4):330-341. [cited by applicant]
Declaration of Dr. Anna Griciuc submitted before the USPTO Patent Trial and Appeal Board for U.S. Appl. No. 15/906,681, filed Feb. 27, 2018, dated Aug. 15, 2019, 7 pages. [cited by applicant]
Ducry et al., (Jan. 2010; e-published on Sep. 21, 2009). “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate Chemistry, 21(1):5-13. [cited by applicant]
Edwards et al., (2003). “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BlyS,” J. Mol. Biol., 334:103-118. [cited by applicant]
Eksioglu et al., (2014). “Novel Therapeutic Approach to Improve Hematopoiesis by Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody,” Blood 124(21):4597, located at < http://www.bloodjournal.… [cited by applicant]
El-Danaf et al., (2015). “Characteristic Patterns of Dendritic Remodeling in Early-Stage Glaucoma: Evidence from Genetically Identified Retinal Ganglion Cell Types,” The Journal of Neuroscience, 35(6):2329-2343. [cited by applicant]
Estep et al., (2013). “High Throughput Solution-Based Measurement Of Antibody-Antigen Affinity And Epitope Binning,” mAbs,. 5(2):270-278. [cited by applicant]
Estus et al., (2013). “Protective Allele Of Cd33 Gwas Snp Decreases Inclusion Of Exon Encoding Ligand Binding Domain; Are Cd33 Antagonists Ad Therapeutics?” 1 page. (Abstract Only). [cited by applicant]
Etemad et al., (2012). “A Novel In Vitro Human Microglia Model: Characterization of Human Monocyte-Derived Microglia,” Journal of Neuroscience Methods, 209:79-89. [cited by applicant]
Fahnestock et al., (2001). “The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease,” Molecular and Cellular Neuroscience, 18:210-220. [cited by applicant]
Fan, Y. J., (2008). “Differential effects of Pro-BDNF on Sensory Neurons after Sciatic Nerve Transection in Neonatal Rats,” European Journal of Neuroscience, 27:2380-2390. [cited by applicant]
Fasen et al., (Feb. 2008; e-published on Dec. 19, 2007). “Ligand Binding Induces Cbl-Dependent EphB1 Receptor Degradation Through the Lysosomal Pathway,” Traffic, 9(2):251-266. [cited by applicant]
Feldhaus et al., (2004, e-pub. May 31, 2004). “Yeast Display of Antibody Fragments: A Discovery and Characterization Platform,” Journal of Immunological Methods, 290:69-80. [cited by applicant]
Fellouse et al., (2004). “Synthetic Antibodies from a Four-Amino-Acid Code: A Dominant Role for Tyrosine in Antigen Recognition,” PNAS, 101(34):12467-12472. [cited by applicant]
Ferlazzo et al., (2000). “Engagement Of CD33 Surface Molecules Prevents the Generation of Dendritic Cells From Both Monocytes and CD34+ Myeloid Precursors,” Eur J Immunol., 30:827-833. [cited by applicant]
Fishwild et al., (1996). “High-Avidity Human Iggκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” Nature Biotechnology, 14:845-851. [cited by applicant]
Gabathuler, R. (2010, e-pub. Aug. 5, 2009). “Approaches to Transport Therapeutic Drugs across the Blood-Brain Barrier to Treat Brain Diseases,” Neurobiology of Disease, 37:48-57. [cited by applicant]
Gawish et al., (Apr. 2015; e.pub Dec. 4, 2014). “Triggering Receptor Expressed on Myeloid cells-2 Fine-Tunes Inflammatory Responses in Murine Gram-Negative Sepsis,” The FASEB Journa,l 29(4):1247-1257. [cited by applicant]
Gerngross, T.U. (Nov. 2004, e-pub. Nov. 4, 2004). “Advances in the Production of Human Therapeutic Proteins in Yeasts and Filamentous Fungi,” Nature Biotechnology, 22(11):1409-1414. [cited by applicant]
Graham et al., (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” Journal of General Virology, 36:59-72. [cited by applicant]
Griciuc et al., (May 22, 2013; e-published on Apr. 25, 2013). “Alzheimer's Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta,” Neuron, 78(4):631-643. [cited by applicant]
Griffin et al., (1984). “A Monoclonal Antibody Reactive with Normal and Leukemic Human Myeloid Progenitor Cells,” Leukemia Research, 8(4):521-534. [cited by applicant]
Griffiths et al., (1993). “Human Anti-Self Antibodies with High Specificity from Phage Display Libraries,” The EMBO Journal, 12(2):725-734. [cited by applicant]
Grobe et al., (2002). “Role of Protein Kinase C in the Phosphorylation of CD33 (Siglec-3) and its Effect on Lectin Activity,” Blood, 99(9):3188-3196. [cited by applicant]
Gruber et al., (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Gupta et al., (2003). “Activated Microglia in Human Retinitis Pigmentosa, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration,” Experimental Eye Research, 76(4):463-471. [cited by applicant]
Hamann et al., (2002, e-pub. Dec. 19, 2001). “Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia,” Bioconjugate Chemistry, 13(1):47-58. [cited by applicant]
Hamers-Casterman et al., (1993). “Naturally Occurring Antibodies Devoid of Light Chains,” Nature, 363:446-448. [cited by applicant]
Handgretinger et al., (1993). “Expression of an Early Myelopoietic Antigen (CD33) of a Subset of Human Umbilical Cord Blood-Derived Natural Killer Cells,” Immunol Lett., 37(2-3):223-228. [cited by applicant]
Harrington et al., (2004). “Secreted proNGF is a Pathophysiological Death-Inducing Ligand After Adult CNS Injury,” Proc. Natl. Acad. Sci USA 101(16):6226-6230. [cited by applicant]
Harris, W.J. (1995). “Therapeutic Monoclonals—Production of Humanized Monoclonal Antibodies for In Vivo Imaging and Therapy,” Biochem. Soc. Transactions, 23(4):1035-1038. [cited by applicant]
Hawkins et al., (1992). “Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation,” Journal of Molecular Biology, 226:889-896. [cited by applicant]
Heider et al., (2012). “A Novel Fc-Engineered Antibody to CD33 with Enhanced ADCC Activity for Treatment of AML,” Blood, 120(21):1363, located at <http://www.bloodjournal.org/content/120/21/1363>, last visited on Jan. 5… [cited by applicant]
Hernández-Caselles et al., (2006). “A Study of CD33 (SIGLEC-3) Antigen Expression and Function on Activated Human T and NK Cells: Two Isoforms of CD33 are Generated by Alternative Splicing,” J Leukoc Biol., 79(1):46-58. [cited by applicant]
Hezareh et al., (2001). “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,” Journal of Virology, vol. 75(24):12161-12168. [cited by applicant]
Holliger et al., (1993). ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences, 90:6444-6448. [cited by applicant]
Hollingworth et al., (May 2011; e-published on Apr. 3, 2011). “Common Variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are Associated with Alzheimer's Disease,” Nat. Genet., 43(5):429-435. [cited by applicant]
Hongo et al., (1995). “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β1,” Hybridoma, 14(3):253-260. [cited by applicant]
Hoogenboom et al., (1992). “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline Hh Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, 227:381-388. [cited by applicant]
Hoyer et al., (2008). “CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues: A New Antibody Shows Excellent Specificity and Sensitivity for Cells of Myelomonocytic Lineage,” Am. J. Clin. Pathol., 129(2):3… [cited by applicant]
Hudson et al. (2003). “Engineered Antibodies,” Nat. Med. 9(1):129-134. [cited by applicant]
Humphrey et al., (2006). “TREM2, a DAP12-Associated Receptor, Regulates Osteoclast Differentiation and Function,” J Bone Miner Res., 21(2):237-245. [cited by applicant]
Hurle et al., (1994). “Protein Engineering Techniques for Antibody Humanization,” Current Opinion in Biotechnology, 5:428-433. [cited by applicant]
Hutchins et al., (1995). “Improved Biodistribution, Tumor Targeting, and Reduced Immunogenicity in Mice with a Gamma 4 Variant of Campath-IH,” Proc. Natl. Acad. Sci., 92:11980-11984. [cited by applicant]
Hutton et al., (1998). “Association of Missense and 5′-Splice-Site Mutations in Tau with the Inherited Dementia FTDP-17,” Nature, 393:702-705. [cited by applicant]
Imai et al., (2006). “Comparing antibody and small-molecule therapies for cancer,” Nat. Rev. Cancer, 6:714-727. [cited by applicant]
Ito et al., (2008). “NOD/Shi-scid IL2rγnull (NOG) Mice More Appropriate for Humanized Mouse Models,” Curr Top Microbiol Immunol., 324:53-76. [cited by applicant]
Ito et al., (May 2012; e-published on Feb. 13, 2012). “Current Advances in Humanized Mouse Models,” Cellular & Molecular Immunology, 9(3):208-214. [cited by applicant]
Jackson et al., (1995). “In Vitro Antibody Maturation. Improvement of a High Affinity, Neutralizing Antibody against IL-1 Beta,” The Journal of Immunology, 157(7):3310-3319. [cited by applicant]
Jakobovits et al., (1993) “Germ-line Transmission and Expression of a Human-derived Yeast Artificial Chromosome,” Nature, 362:255-258. [cited by applicant]
Jakobovits et al., (1993). “Analysis of Homozygous Mutant Chimeric Mice: Deletion of The Immunoglobulin Heavy-chain Joining Region Blocks B-Cell Development and Antibody Production,” Proceedings of the National Academy … [cited by applicant]
Jandus et al., (Aug. 15, 2011; e-published on May 31, 2011). “Targeting Siglecs—A Novel Pharmacological Strategy For Immuno- and Glycotherapy,” Biochem. Pharmacol., 82(4):323-332. [cited by applicant]
Jansen et al., (Nov. 2007, e-pub. Oct. 14, 2007). “Roles for the Pro-Neurotrophin Receptor Sortilin in Neuronal Development, Aging and Brain Injury,” Nature Neuroscience, 10(11):1449-1457. [cited by applicant]
Jiang et al., (2014). “CD33 in Alzheimer's Disease,” Mol. Neurobiol., 49:529-535. [cited by applicant]
Johnson et al., (1993). “Human antibody engineering: Current Opinion in Structural Biology,” Current Opinion in Structural Biology, 3(4):564-571. [cited by applicant]
Jones et al., (1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,” Nature, 321:522-525. [cited by applicant]
Jurcic, J.G., (Mar. 2012, e-pub. Nov. 23, 2011). “What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?,” Curr Hematol Malig Rep, 7(1):65-73. [cited by applicant]
Karch et al., (2012). “Expression of Novel Alzheimer's Disease Risk Genes in Control and Alzheimer's Disease Brains,” PLOS One, 7(11):1-9. [cited by applicant]
Kelm et al., (1994). “Sialoadhesin, Myelin-Associated Glycoprotein and CD22 Define a New Family of Sialic Acid-Dependent Adhesion Molecules of the Immunoglobulin Superfamily,” Current Biology, 4(11):965-972. [cited by applicant]
Keren-Shaul et al., (2017). “A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease,” Cell, 169:1276-1290. [cited by applicant]
Kirkland et al., (1986). “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies,” J. Immunol., 137:3614-3619. [cited by applicant]
Koga et al., (2004). “Costimulatory Signals Mediated by the ITAM Motif Cooperate with RANKL for Bone Homeostasis,” Nature, 428:758-763. [cited by applicant]
Köhler et al., (1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature, 256:495-497. [cited by applicant]
Kostelny et al., (1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology, 148(5):1547-1553. [cited by applicant]
Kozbor et al., (1984). “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies,” The Journal of Immunology, 133(6):3001-3005. [cited by applicant]
Laird et al., (2010). “Progranulin is Neurotrophic in Vivo and Protects against a Mutant TDP-43 Induced Axonopathy,” PLOS One, 5(10):e13368, 7 pages. [cited by applicant]
Lajaunias et al., (Jan. 2005; e-published on Dec. 16, 2004). “Constitutive Repressor Activity of CD33 on Human Monocytes Requires Sialic Acid Recognition and Phosphoinositide 3-Kinase-Mediated Intracellular Signaling,” … [cited by applicant]
Langer, R., (1990). “New Methods of Drug Delivery,” Science 249(4976):1527-1533. [cited by applicant]
Lartigue, J.D. (2012). “Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells,” OncologyLive, available online at <https://www.onclive.com/view/antibody-drug-conjugates-guided-missiles-deployed-agai… [cited by applicant]
Lavail et al., (2011). “Retinal Degeneration Rat Model Resource Availability of P23H and S334ter Mutant Rhodopsin Transgenic Rats and RCS Inbred and RCS Congenic Strains of Rats,” University of California, 12 pages. [cited by applicant]
Lazar et al., (2006). “Engineered Antibody Fc variants with Enhanced Effector Function,” PNAS, 103(11):4005-4010. [cited by applicant]
Lee et al., (2003). “Bivalent Antibody Phage Display Mimics Natural Immunoglobulin,” Journal of Immunological Methods, 284(1-2):119-132. [cited by applicant]
Lee et al., (2004). “High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold,” Journal of Molecular Biology, 340:1073-1093. [cited by applicant]
Li et al., (2006). “Human Antibodies for Immunotherapy Development Generated via a Human B Cell Hybridoma Technology,” PNAS, 103(10):3557-3562. [cited by applicant]
Li et al., (2006). “Optimization of Humanized IgGs in Glycoengineered Pichia Pastoris,” Nature Biotechnology, 24(2):210-215. [cited by applicant]
Li et al., (Aug. 19, 2011). “Inhibitory Fcgamma Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies,” Science, 333(6045):1030-1034. [cited by applicant]
Lightle et al., (Mar. 24, 2010; e-published on Jan. 29, 2010). “Mutations Within a Human Lgg2 Antibody Form Distinct and Homogeneous Disulfide Isomers but do not Affect Fc Gamma Receptor or C1q Binding,” Protein Science… [cited by applicant]
Lipovsek et al., (2004, e-pub. May 31, 2004). “In-vitro protein evolution by ribosome display and mRNA display,” Journal of Immunological Methods, 290:51-67. [cited by applicant]
Lloyd et al., (2009). “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng. Design & Select, 22(3):159-168. [cited by applicant]
Lonberg et al., (1994). “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature, 368:856-859. [cited by applicant]
Lonberg et al., (1995). “Human Antibodies from Transgenic Mice,” International Reviews of Immunology., 13:65-93. [cited by applicant]
Lonberg. (2008). “Fully Human Antibodies From Transgenic Mouse and Phage Display Platforms,” Curr. Opin. Immunol. 20(4):450-459. [cited by applicant]
Low et al., (2013). “Animal Models of Ulcerative Colitis and their Application in Drug Research,” Drug Design, Development and Therapy, 7:1341-1357. [cited by applicant]
LüTje et al., (2014). “Anti-CEA Antibody Fragments Labeled with [18F]AIF for PET Imaging of CEA-Expressing Tumors,” Bioconjugate Chemistry, 25(2):335-341. [cited by applicant]
Macauley et al., (Oct. 2014; e-published on Sep. 19, 2014). “Siglec Regulation of Immune Cell Function in Disease,” Nature Reviews Immunology, 14(10):653-666, 29 pages. [cited by applicant]
Malik et al., (2013). “CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing,” J. Neurosci, 33(33):13320-13325. [cited by applicant]
Malik et al., (Nov. 1, 2015; e-published on Aug. 6, 2015). “VPS35 Pathogenic Mutations Confer no Dominant Toxicity but Partial Loss of Function in [cited by applicant]
Marks et al., (1991). “By-passing immunization: Human antibodies from V-gene libraries displayed on phage,” Journal of Molecular Biology, 222(3): 581-597. [cited by applicant]
Marks et al., (1992).“By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling,” Bio/Technology, 10:779-782. [cited by applicant]
Martens et al., (2012). “Progranulin Deficiency Promotes Neuroinflammation and Neuron Loss Following Toxin-Induced Injury,” The Journal of Clinical Investigation, 122(11):3955-3959. [cited by applicant]
Mather et al., (1982). “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Annals of the New York Academy of Sciences, Testicular Cell Culture, 383:44-68. [cited by applicant]
Mather, J.P. (1980). “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biology of Reproduction, 23:243-252. [cited by applicant]
May et al., (1998). “Crystal Structure of the N-Terminal Domain of Sialoadhesin in Complex with 3′ Sialyllactose at 1.85 A Resolution,” Molecular Cell, 1(5):719-728. [cited by applicant]
Mccafferty et al., (1990). “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature, 348:552-554. [cited by applicant]
Mcearchern et al., (Feb. 1, 2007, e-pub. Oct. 12, 2006). “Engineered Anti-CD70 Antibody with Multiple Effector Functions Exhibits in Vitro and in Vivo Antitumor Activities,” Blood, 109(3):1185-1192. [cited by applicant]
Mcmillan et al., (Aug. 11, 2008; e-published on Jan. 17, 2008). “CD33-related Sialic-Acid-Binding Immunoglobulin-Like Lectins in Health and Disease,” Carbohydrate Research, 343(12):2050-2056. [cited by applicant]
Milstein et al., (Oct. 6, 1983). “Hybrid Hybridomas and their use in Immunohistochemistry,” Nature, 305:537-540. [cited by applicant]
Mizoguchi, A. (2012). “Animal Models of Inflammatory Bowel Disease,” Progress in Molecular Biology and Translational Science, 105:263-320, fifty eight pages. [cited by applicant]
Moldenhauer et al., (1990). “Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia,” Scand. J. Immunol., 32:77-82. [cited by applicant]
Monsonego-Oran et al., (Sep. 25, 2002; e-published on Aug. 28, 2002). “FGF Receptors Ubiquitylation: Dependence on Tyrosine Kinase Activity and Role in Downregulation,” FEBS Letters, 528(1-3):83-89. [cited by applicant]
Morel et al., (1988). “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations,” Molec. Immunol., 25:7-15. [cited by applicant]
Morimoto et al., (1992). “Single-Step Purification of F(ab')2 Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW,” Jou… [cited by applicant]
Morrison et al., (Nov. 1984). “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains,” Proc. Nat'l Acad. Sci, 81:6851-6855. [cited by applicant]
Morrison, S.L. (Apr. 28, 1994). “Success in Specification,” Nature, 368:812-813. [cited by applicant]
Mortland et al., (Feb. 26, 2013). “Clinical Significance of CD33 Nonsynonymous SingleNucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy,… [cited by applicant]
Munson et al., (1980). “Ligand: A Versatile Computerized Approach for Characterization of Ligand-binding Systems,” Analytical Biochemistry, 107:220-239. [cited by applicant]
Naito et al., (2000). “Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody (gemtuzumab zogamicin, CMA-676) Shows Cytocidal effect on CD33-Positive Leukemia Cell Lines, But is Inactive on P-glycoprotein-Expr… [cited by applicant]
Naj et al., (May 2011; e-published on Apr. 3, 2011). “Common Variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are Associated with Late-onset Alzheimer's Disease,” Nat Genet., 43(5):436-441, 17 pages. [cited by applicant]
Nakamura et al., (2007).“Intracellular Sortilin Expression Pattern Regulates proNGF-Induced Naturally Occurring Cell Death during Development,” Cell Death and Differentiation, 14:1552-1554. [cited by applicant]
NCBI Blast RID-WN0V0GA1114, Seq ID No. 1 vs. murine CD33, submitted Apr. 12, 2020, 3 pages. [cited by applicant]
Neary et al., (1998). “Frontotemporal Lobar Degeneration: A Consensus on Clinical Diagnostic Criteria,” Neurology, 51:1546-1554. [cited by applicant]
Neuberger, M., (1996). “Generating high-avidity human Mabs in mice,” Nature Biotechnology, 14:826, 1 page. [cited by applicant]
Neumann et al., (2007). “TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis,” Arch Neurol., 64(10):1388-1394. [cited by applicant]
Novack et al., (2008). “The Osteoclast: Friend or Foe?,” Annu. Rev. Pathol. Mech. Dis., 3:457-484. [cited by applicant]
Nykjaer et al., (2004). “Sortilin is Essential for proNGF Induced Neuronal Cell Death,” Nature, 427:843-848. [cited by applicant]
Nykjaer et al., (2005, e-pub. Jan. 26, 2005). “p75NTR—Live or Let Die,” Current Opinion in Neurobiology, 15:49-57. [cited by applicant]
Oganesyan et al., (2008). “Structural characterization of a Human Fc Fragment Engineered for Lack of Effector Functions,” Acta Crystallography, 64:700-704. [cited by applicant]
Ohgidani et al., (2014). “Direct induction of ramified microglia-like cells from human monocytes: Dynamic microglial dysfunction in Nasu-Hakola disease,” Scientific Reports, 4(Article No. 4957):1-7. [cited by applicant]
O'reilly et al., (May 2009; e-published on Apr. 7, 2009). “Siglecs as Targets for Therapy in Immune Cell Mediated Disease,” Trends Pharmacol. Sci., 30(5):240-248, 23 pages. [cited by applicant]
Otero et al., (2012; e-published on Feb. 6, 2012). “TREM2 and β-Catenin Regulate Bone Homeostasis by Controlling the Rate of Osteoclastogenesis,” J Immunol, 188:2612-2621. [cited by applicant]
Park et al., (2015). “Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Promotes Adipogenesis and Diet-Induced Obesity,” Diabetes, 64:117-127. [cited by applicant]
Paul et al., (2000). “Myeloid Specific Human CD33 is an Inhibitory Receptor With Differential ITIM Function in Recruiting the Phosphatases SHP-1 and SHP-2,” Blood, 96(2):483-490. [cited by applicant]
Peiper et al., (1988). “Molecular Cloning, Expression, and Chromosomal Localization of a Human Gene Encoding the CD33 Myeloid Differentiation Antigen,” Blood, 72(1):314-321. [cited by applicant]
Peng et al., (2010). “TREM2- and DAP12-Dependent Activation of PI3K Requires DAP10 and Is Inhibited by SHIP1,” Science Signaling, 3(122):ra38, pp. 1-15. [cited by applicant]
Pennesi et al., (2012). “Animal Models of Age Related Macular Degeneration,” Molecular Aspects of Medicine, 33(4):487-509, forty pages. [cited by applicant]
Pérez-Oliva et al., (Jun. 1, 2011; e-published on Jan. 28, 2011). “Epitope Mapping, Expression and Post-Translational Modifications of Two Isoforms Of CD33 (CD33M and CD33m) on Lymphoid and Myeloid Human Cells,” Glycobi… [cited by applicant]
Peters, S.J. et al. (2012). “Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability,” The Journal of Biological Chemistry 287(29):24525-24533. [cited by applicant]
Pillai et al., (2012; Jan. 3, 2012). “Siglecs and Immune Regulation,” Annu. Rev. Immunol., 30:357-392. [cited by applicant]
Plückthun, A., (1992). “Mono- and Bivalent Antibody Fragments Produced in [cited by applicant]
Poduslo et al., (1994). “Macromolecular Permeability Across the Blood-Nerve and Blood-Brain Barriers,” Proc. Natl. Acad. Sci. USA, 91:5705-5709. [cited by applicant]
Pollenz et al., (Dec. 1, 2006, e-pub. Aug. 25, 2006). “Ligand-Dependent and -Independent Degradation of the Human Aryl Hydrocarbon Receptor (hAHR) in Cell Culture Models,” Chemico-Biological Interactions, 164(1-2):49-59. [cited by applicant]
Presta et al., (1993). “Humanization of an Antibody Directed Against IgE,” The Journal of Immunology, 151(5):2623-2632. [cited by applicant]
Presta, L.G., (1992). “Antibody Engineering,” Current Opinion in Structural Biology, 2:593-596. [cited by applicant]
Provenzano, M.J., (2008). “p75NTR and Sortilin Increase After Facial Nerve Injury,” Laryngoscope, 118:87-93. [cited by applicant]
Raj et al., (May 15, 2014; e-published on Dec. 30, 2013). “CD33: Increased Inclusion of Exon 2 Implicates the Ig V-Set Domain in Alzheimer's Disease Susceptibility,” Human Molecular Genetics, 23(10):2729-2736. [cited by applicant]
Ratnavalli et al., (2002). “The Prevalence of Frontotemporal Dementia,” Neurology, 58(1 of 2):1615-1621. [cited by applicant]
Ravetch et al., (1991). “Fc Receptors,” Annual Review Immunology, 9:457-492. [cited by applicant]
Reddy et al., (2000). “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” The Journal of Immunology, 164:1925-1933. [cited by applicant]
Ricart, A.D., (2011). “Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin,” Clin Cancer Res, 17(20):6417-6427. [cited by applicant]
Riechmann et al., (1988). “Reshaping Human Antibodies for Therapy,” Nature, 332:323-327. [cited by applicant]
Roberts et al., (1997). “RNA-Peptide Fusions for the In Vitro Selection of Peptides and Proteins,” Proc. Natl. Acad. Sci. USA, 94:12297-12302. [cited by applicant]
Rollins-Raval et al., (May 2012; e-published on Feb. 20, 2012). “The Value of Immunohistochemistry for CD14, CD123, CD33, Myeloperoxidase And CD68R in the Diagnosis of Acute and Chronic Myelomonocytic Leukaemias,” Histo… [cited by applicant]
Rosok et al., (1996). “Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” The Journal of Biological Chemistry, 271(37):22611-22618. [cited by applicant]
Sazinsky et al., (2008). “Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors,” PNAS, 105(51):20167-20172. [cited by applicant]
Schabbauer et al., (2010). “Myeloid PTEN Promotes Inflammation but Impairs Bactericidal Activities During Murine Pneumococcal Pneumonia,” The Journal of Immunology, 185(1):468-476. [cited by applicant]
Schaffitzel et al., (1999). “Ribosome Display: An In Vitro Method for Selection and Evolution of Antibodies from Libraries,” Journal of Immunological Methods, 231:119-135. [cited by applicant]
Schier et al., (1996). “Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis,” Gene, 169:147-155. [cited by applicant]
Schymick et al., (2007). “Progranulin Mutations and Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Phenotypes,” Journal of Neurology, Neurosurgery and Psychiatry, 78:754-756. [cited by applicant]
Seno et al., (2009). “Efficient Colonic Mucosal Wound Repair Requires Trem2 Signaling,” PNAS, 106(1):256-261. [cited by applicant]
Shalaby et al., (1992). “Development of Humanized Bispecitic Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene,” The Journal of Experimental Medicine, 175:217-225. [cited by applicant]